Cardiothoracic & vascular anesthesia

Comparison of 4% Albumin and Ringer's Acetate on Hemodynamics in On-pump Cardiac Surgery: An Exploratory Analysis of a Randomized Clinical Trial

J Cardiothorac Vasc AnesthPublished Exploratory analysis of the ALBICS randomised trial

Authors' conclusion

In on-pump cardiac surgery, hypotension and hyperlactatemia are associated with the occurrence of ≥1 MAE. Compared with Ringer's acetate, albumin did not decrease hypotension and decreased hyperlactatemia only late postoperatively.

Study context

Population
On-pump cardiac surgical patients, Helsinki University Hospital
Participants
1,386 patients
Comparison
Albumin vs Ringer's
Primary endpoint
Incidence of hypotension (time-weighted average MAP <65 mmHg) and hyperlactatemia (time-weighted average blood lactate >2 mmol/L)
Follow-up
Operating room, early (0-6 h) and late (6-24 h) postoperatively
Methodological detailsdouble-blind, single-centre
  • Double-blind
  • Single-centre

Primary result

As reported in the abstract

Hypotension · operating room

P > 0.05

Further findings

Hypotension · early postoperatively (0-6 h)

P > 0.05

Hypotension · late postoperatively (6-24 h)

P > 0.05

Hyperlactatemia · operating room · after Bonferroni-Holm correction

P > 0.025

Hyperlactatemia · early postoperatively (0-6 h) · after Bonferroni-Holm correction

P > 0.025

Hyperlactatemia · late postoperatively (6-24 h)

P < 0.001

Overall counts (operating room, early, late postoperatively)

Hypotension
118, 48, and 17 patients
Hyperlactatemia
313, 131, and 83 patients

Association with ≥1 MAE (ALBICS primary outcome)

Hypotension and hyperlactatemia associated with MAE occurrence

Original publication

Comparison of 4% Albumin and Ringer's Acetate on Hemodynamics in On-pump Cardiac Surgery: An Exploratory Analysis of a Randomized Clinical Trial. J Cardiothorac Vasc Anesth. Published 20 July 2024. doi:10.1053/j.jvca.2024.07.025

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.